Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the study is the evaluation of the safety and tolerability of FAB117-HC (a medicinal product containing human allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed with H2O2, HC016 cells) administered at a single-time point to patients with acute thoracic traumatic spinal cord injury (SCI). The study will also include initial exploration of potential clinical efficacy. Dose levels of 20 million and 40 million cells will be administered.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Versus Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal Injection for SCI

NCT05018793

Spinal Cord Injuries

RECRUITING PHASE1

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI

NCT05152290

Spinal Cord Injuries

RECRUITING PHASE1

Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain

NCT00443781

Low Back Pain

COMPLETED PHASE4

Duraplasty for Acute Traumatic Spinal Cord Injury

NCT07280351

Spinal Cord Injury, Acute Spinal Cord Injury (SCI), Initial Encounter Spinal Cord Injury Cervical

NOT_YET_RECRUITING NA

Clinical Trial Using Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury

NCT02923817

Spinal Cord Injuries

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

FAB117-HC is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2.

The main purpose of this study is to evaluate the safety and tolerability of a single administration of FAB117-HC using: a) two sequential escalating doses administered between 72 and 120 hours post-injury, to patients with acute traumatic SCI with ASIA Impairment Scale (AIS) grade A; and b) the determined maximum tolerated dose administered up to 96 h post-injury to patients with AIS grading of A or B. The study includes also initial exploration of efficacy.

Treatment is administered by intramedullary injection into the injured spinal cord, during the decompression and stabilization surgery (DSS) of the fracture. DSS is routinely performed on almost all SCI patients.

The study has been divided into two phases:

Phase 1 (open label): 8 AIS A patients with lesion located between D1 and D12 will be included in 2 sequential cohorts.

Phase 2 (randomized, controlled, double-blind): Up to 40 AIS A or B patients with lesion located between D1 and D12, will be randomly divided into two groups (control and treated) that will be balanced in AIS grade.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Traumatic Spinal Cord Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FAB117-HC (Ph 1)

Patients with acute traumatic spinal cord injury grading AIS A (8 patients)

Group Type EXPERIMENTAL

FAB117-HC

Intervention Type DRUG

(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)

Control group (Ph 2)

Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)

Group Type OTHER

Control group

Intervention Type OTHER

(Ph 2) No treatment will be administered

FAB117-HC (Ph 2)

Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)

Group Type EXPERIMENTAL

FAB117-HC

Intervention Type DRUG

(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FAB117-HC

(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)

Intervention Type DRUG

Control group

(Ph 2) No treatment will be administered

Intervention Type OTHER

FAB117-HC

(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Phase 1 (2 Cohorts)

1. Male or female subjects ≥ 16 to ≤ 70 years.
2. ASIA impairment grade A.
3. Either a level of injury between D1-D12 both inclusive (cohorts 1 and 2).
4. Single traumatic spinal cord injury as defined by MRI.
5. Injury occurred between 72 and 120h before undergoing DSS and treatment.
6. Clinically and haemodynamically stable, under medical criteria, enough to undergo DSS.
7. Able to give informed consent either in writing or orally in the presence of a witness.

Phase 2 (2 Groups)

1. Male or female subjects ≥ 16 to ≤ 70 years.
2. ASIA impairment grade A or B.
3. An injury between D1 and D12, both inclusive.
4. Single traumatic spinal cord injury as defined by MRI.
5. Injury occurring up to 96 h before undergoing DSS and treatment.
6. Clinically and haemodynamically stable enough, under medical criteria, to undergo DSS.
7. Able to give informed consent either in writing or orally in the presence of a witness.

Exclusion Criteria

1. Participated in a previous clinical study and received an investigational product within 28 days of SCI (within 5 years of SCI if the investigational product is a cell-based medicine).
2. Radiological or MRI or DSS evidence of complete or partial spinal cord transection.
3. Inability to unequivocally identify the injection sites.
4. Multiple injuries to the neurological spinal cord at different levels.
5. Patients with any of these additional conditions:

1. Penetrating spinal cord injuries.
2. Associated trauma or injury to the brachial and / or lumbosacral plexus.
6. Active infection in the surgical area.
7. Haemodynamic instability contraindicating DSS procedure in the time frame defined for inclusion in the trial.
8. Multiple organ failure.
9. Severe multiple trauma that hampers the stabilization procedure in the defined term for the inclusion in the trial.
10. Significant head injury (Score on the Glasgow scale less than or equal to 13 and / or abnormal MRI/CT, meaning oedema, axonal lesion and/or haemorrhage) or other injury that in the investigator's opinion is sufficient to interfere with the assessment of spinal cord function or compromise the validity of patient data.
11. Patients undergoing mechanical ventilation that does not allow a prior clinical examination.
12. Inability to communicate with the neurological examiner so that the validity of patient data could be unreliable.
13. Coma or significant impairment in the level of consciousness, including unconsciousness due to sedative-analgesic medications, that interferes with the performance or interpretation of assessments specific in the protocol.
14. Preexisting or current significant diseases such as hepatitis C, HIV, epilepsy, neoplastic disease or other diseases that could cause neurological deficits including syphilis, myelopathy, and polyneuropathy.
15. Background or acute episode of Guillain-Barre syndrome.
16. History of meningitis or meningoencephalitis.
17. Current autoimmune disease treated with immunosuppressant therapy.
18. Patients with history of severe thrombophilia or under anticoagulant pharmacological therapy which long elimination half-live prevents a rapid transition to heparin (like dabigatran and rivaroxaban).
19. Presence of any psychiatric illness, as defined by the DSM-IV-TR, or medically unstable illness that means a hindrance to the adherence to rehabilitation and/or to the informed consent signature.
20. Pregnant women or women of childbearing age who are not using an appropriate method of contraception and, moreover, are not willing to continue to use it for the duration of the trial. If the patient is menopausal or sterile, it must be documented in the medical record.
21. Women who are breastfeeding if unwilling to stop at the time of recruitment.
22. History of allergy with anaphylactic shock.
23. Patients with known hypersensitivity to any of the excipients of FAB117-HC.
24. Patients with known hypersensitivity to penicillin, streptomycin, enzymes (trypsin or collagenase), bovine serum or DMSO.

Minimum Eligible Age

16 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No